|
“Companies
know they can turn a challenging drug compound into a real win if
solubilization difficulties can be overcome. Now, when off-the-shelf
remedies don’t work, BioAqueous services offer them more alternatives in
the form of advanced, customized solubilization solutions.”
“Advanced
solubilization technologies can potentially enhance both ongoing drug
candidate development and the value of drugs currently on the market,”
said Ronald L. Smith, Ph.D., Executive Director of Exploratory
Biopharmaceutical Research and Stability for Bristol-Myers Squibb’s
Pharmaceutical Research Institute. “This agreement expands our portfolio
of options to apply technology solutions to address drug solubilization
challenges.”
Technologies
developed by Dow show the ability to alter particle size, surface area, or
morphology to create nanostructured particles that can improve a drug's
ability to dissolve in the body. Based on the specific challenges of a
particular drug compound, an initial feasibility study employs Dow’s
portfolio of advanced particle engineering technologies to develop
customized solutions to meet the desired performance objectives of the
compound. Beyond a
feasibility study, BioAqueous solubilization services include support
through all stages of development, optimization, and production of
clinical supplies.
BioAqueous
services also offer cGMP manufacturing of particles at commercial scale.
More information is available at www.bioaqueous.com.
About Bristol-Myers Squibb
Bristol-Myers
Squibb is a global pharmaceutical and related health care products company
whose mission is to extend and enhance human life. To learn more about
Bristol-Myers Squibb, visit www.bms.com
|
|
|
About Dowpharma
Dowpharma
serves the pharmaceutical and biopharmaceutical industries with innovative
technology, products, and services for clients in drug discovery,
development, manufacturing, and delivery. Dowpharma combines the resources
and capabilities of several offerings to create a single, market-focused
organization with broad service and support capabilities for large and
emerging pharmaceutical companies.
Dowpharma
services include process development, route selection, methods
development, custom solubilization, chiral capabilities, and associated
analytical services, as well as manufacturing and scale-up from
feasibility, through clinical trials, to commercial manufacturing.
Dowpharma currently manufactures small molecule Active Pharmaceutical
Ingredients (APIs) and intermediates, oligonucleotides, cGMP polymers,
peptides and therapeutic proteins from microbial fermentation and
plant-based technologies.
Dowpharma
draws upon a 20-year history of excellent cGMP regulatory compliance in
the organic synthesis of APIs and pharmaceutical intermediates with the
ability to provide client support in filing and validation strategies.
Dowpharma operates research, process development, and manufacturing
facilities in North America and Europe. More information is available at
www.dowpharma.com.
About
Dow
Dow is a leader in science
and technology, providing innovative chemical, plastic and agricultural
products and services to many essential consumer markets. With annual
sales of $33 billion, Dow serves customers in more than 180 countries and
a wide range of markets that are vital to human progress, including food,
transportation, health and medicine, personal and home care, and building
and construction, among others. Committed to the principles of sustainable
development, Dow and its approximately 46,000 employees seek to balance
economic, environmental and social responsibilities. References to
“Dow” or the “Company” mean The Dow Chemical Company and its
consolidated subsidiaries unless otherwise expressly noted.
For further information, visit www.dow.com.
Forward-looking
statements (statements which are not historical facts) in this release are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors of both Dow and Bristol-Myers
Squibb are cautioned that all forward-looking statements involve risks and
uncertainties.
For editorial information,
please contact Adrianne Proctor, The Dow Chemical Company (ph)
989-636-5636, or
Josiah McClellan, Gibbs
& Soell (ph) 212-697-2600.
#
# #
|
